Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma

Código QR

Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma

Guardado en:

Detalles Bibliográficos
Autores principales:	Sanju Cyriac, Ajith Toms, Sunitha Thomas
Formato:	article
Lenguaje:	EN
Publicado:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/eb325987792a48099d094465812ff599
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission
por: Richard Carvajal, et al.
Publicado: (2021)

Pembrolizumab-induced massive hypereosinophilia associated with mononeuritis multiplex, brain microvascular lesions and intestinal eosinophilic infiltration in a melanoma patient
por: Kim Dao, et al.
Publicado: (2021)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Frank Riemer, et al.
Publicado: (2021)

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
por: Antoni Ribas, et al.
Publicado: (2020)

Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
por: Hui Zheng, et al.
Publicado: (2021)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Thomas F Gajewski, et al.
Publicado: (2021)

Correction: Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
Publicado: (2021)

Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis
por: Anders Wilder Erickson, et al.
Publicado: (2021)

Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection
por: Alexa C. Glencer, et al.
Publicado: (2021)

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
por: Álamo MC, et al.
Publicado: (2021)

Metastatic cervical cancer: clinical experience with pembrolizumab application. Case report
por: Anna E. Protasova, et al.
Publicado: (2021)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Mary L Disis, et al.
Publicado: (2021)

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
por: Naoya Maekawa, et al.
Publicado: (2021)

Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer
por: Ciara H. O’Flanagan, et al.
Publicado: (2017)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Jie Zhang PhD, et al.
Publicado: (2021)

Pembrolizumab provides long‐term survival benefits in advanced non‐small cell lung cancer: The 5‐year outcomes of the KEYNOTE‐024 trial
por: Fengtan Li, et al.
Publicado: (2021)

Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites
por: Soojin Cha, et al.
Publicado: (2021)

Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
por: Yuki Katsumata, et al.
Publicado: (2021)

Taxanes in the elderly patient with metastatic breast cancer
por: Yardley DA
Publicado: (2015)

Moonshots and metastatic disease: the need for a multi-faceted approach when studying atypical responses
por: Kristine De La Torre, et al.
Publicado: (2017)

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
por: Yardley DA
Publicado: (2019)

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy
por: Pascale Lejeune, et al.
Publicado: (2021)

Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma
por: Corey Smith, et al.
Publicado: (2021)

Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
por: Jin Yuan MD, et al.
Publicado: (2021)

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
por: Omid Hamid, et al.
Publicado: (2021)

Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
por: Toshiki Kijima, et al.
Publicado: (2021)

Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer
por: Ying L. Liu, et al.
Publicado: (2021)

Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment
por: Julia Stevenson, et al.
Publicado: (2021)

PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN
por: Yifei Qin, et al.
Publicado: (2021)

Ferroptosis-Associated Classifier and Indicator for Prognostic Prediction in Cutaneous Melanoma
por: Hao Zeng, et al.
Publicado: (2021)

Correction: Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
Publicado: (2021)

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
por: Maurício Fernando Silva Almeida Ribeiro, et al.
Publicado: (2021)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns MW, et al.
Publicado: (2015)

PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls
por: A. Franza, et al.
Publicado: (2022)

BAP1 methylation: a prognostic marker of uveal melanoma metastasis
por: Mathieu F. Bakhoum, et al.
Publicado: (2021)

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer
por: Amanda Bortolini Silveira, et al.
Publicado: (2021)

TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
por: Michael Conroy, et al.
Publicado: (2021)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki M
Publicado: (2014)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
por: Weise AM, et al.
Publicado: (2014)

Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report
por: Tian Zeng, et al.
Publicado: (2021)